NCI-MATCH-H

NCT02465060 📎

Regimen

Experimental
Dabrafenib 150 mg PO BID + trametinib 2 mg PO QD
Control
single-arm / no comparator

Population

BRAF V600E-mutated advanced solid tumors excluding melanoma and NSCLC (those were covered by dedicated arms); pan-cancer basket including CCA/BTC among several tumor types. BTC/CCA subgroup n=7-8 of 35 total; exact BTC N reported in primary publication. All enrolled after ≥1 prior therapy. BRAF V600E detected by central CLIA-certified molecular testing (NCI-MATCH trial molecular screening).

Key finding

NCI-MATCH subprotocol H independently confirmed tumor-agnostic BRAF V600E targeting with dab+tram in non-melanoma, non-NSCLC solid tumors. The BTC/CCA patients in this trial showed responses consistent with ROAR BTC data, providing cross-study validation. The small BTC subgroup (n=7-8) in NCI-MATCH H limits definitive conclusions for BTC alone, but collectively with ROAR (n=43), the evidence base for dab+tram in BRAF V600E CCA is robust.

Source: PMID 32758030

Timeline

    Guideline citations

    • NCCN BTC (p.34)